British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...

GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Shares of GSK PLC GSK inched down 0.34% to £16.04 Wednesday, on what proved to be an all-around rough trading session for the ...

Drug maker GSK plc (GSK, GSK.L) confirmed Wednesday that it has reached two confidential settlements in cases filed in California ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.